559 related articles for article (PubMed ID: 27389786)
1. The Evolving and Future Role of Taxanes in Squamous Cell Carcinomas of the Head and Neck: A Review.
Mody MD; Gill HS; Saba NF
JAMA Otolaryngol Head Neck Surg; 2016 Sep; 142(9):898-905. PubMed ID: 27389786
[TBL] [Abstract][Full Text] [Related]
2. Concurrent therapy with taxane versus non-taxane containing regimens in locally advanced squamous cell carcinomas of the head and neck (SCCHN): a systematic review.
Behera M; Owonikoko TK; Kim S; Chen Z; Higgins K; Ramalingam SS; Shin DM; Khuri FR; Beitler JJ; Saba NF
Oral Oncol; 2014 Sep; 50(9):888-94. PubMed ID: 25060589
[TBL] [Abstract][Full Text] [Related]
3. Docetaxel in the management of patients with head and neck squamous cell carcinoma.
Bernier J; Vrieling C
Expert Rev Anticancer Ther; 2008 Jul; 8(7):1023-32. PubMed ID: 18588449
[TBL] [Abstract][Full Text] [Related]
4. Randomized controlled phase II comparison study of concurrent chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil versus CCRT with cisplatin, 5-fluorouracil, methotrexate and leucovorin in patients with locally advanced squamous cell carcinoma of the head and neck.
Tsukuda M; Ishitoya J; Matsuda H; Horiuchi C; Taguchi T; Takahashi M; Nishimura G; Kawakami M; Watanabe M; Niho T; Kawano T; Ikeda Y; Sakuma Y; Shiono O; Komatsu M
Cancer Chemother Pharmacol; 2010 Sep; 66(4):729-36. PubMed ID: 20033810
[TBL] [Abstract][Full Text] [Related]
5. Docetaxel induction therapy in locally advanced squamous cell carcinoma of the head and neck.
Posner MR; Lefebvre JL
Br J Cancer; 2003 Jan; 88(1):11-7. PubMed ID: 12556952
[TBL] [Abstract][Full Text] [Related]
6. Integration of taxanes into primary chemotherapy for squamous cell carcinoma of the head and neck: promise fulfilled?
Brockstein B
Curr Opin Oncol; 2000 May; 12(3):221-8. PubMed ID: 10841194
[TBL] [Abstract][Full Text] [Related]
7. Toxicities of systemic agents in squamous cell carcinoma of the head and neck (SCCHN); A new perspective in the era of immunotherapy.
Saba NF; Mody MD; Tan ES; Gill HS; Rinaldo A; Takes RP; Strojan P; Hartl DM; Vermorken JB; Haigentz M; Ferlito A
Crit Rev Oncol Hematol; 2017 Jul; 115():50-58. PubMed ID: 28602169
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel (Taxol)/ifosfamide-based chemotherapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Shin DM
Semin Oncol; 2000 Feb; 27(1 Suppl 1):36-40. PubMed ID: 10697043
[TBL] [Abstract][Full Text] [Related]
9. Docetaxel in squamous cell cancer of the head and neck.
Posner MR
Anticancer Drugs; 2001 Feb; 12 Suppl 1():S21-4. PubMed ID: 11340900
[TBL] [Abstract][Full Text] [Related]
10. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
Goble S; Bear HD
Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
[TBL] [Abstract][Full Text] [Related]
11. Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Haddad R; Colevas AD; Tishler R; Busse P; Goguen L; Sullivan C; Norris CM; Lake-Willcutt B; Case MA; Costello R; Posner M
Cancer; 2003 Jan; 97(2):412-8. PubMed ID: 12518365
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck.
Colevas AD
J Clin Oncol; 2006 Jun; 24(17):2644-52. PubMed ID: 16763278
[TBL] [Abstract][Full Text] [Related]
13. A Phase I/II trial of concurrent docetaxel and radiation after induction chemotherapy in patients with poor prognosis squamous cell carcinoma of the head and neck.
Tishler RB; Norris CM; Colevas AD; Lamb CC; Karp D; Busse PM; Nixon A; Frankenthaler R; Lake-Willcutt B; Costello R; Case M; Posner MR
Cancer; 2002 Oct; 95(7):1472-81. PubMed ID: 12237916
[TBL] [Abstract][Full Text] [Related]
14. Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directions.
Haddad RI; Posner M; Hitt R; Cohen EEW; Schulten J; Lefebvre JL; Vermorken JB
Ann Oncol; 2018 May; 29(5):1130-1140. PubMed ID: 29635316
[TBL] [Abstract][Full Text] [Related]
15. Taxanes in cancer of the head and neck.
Misiukiewicz K; Gupta V; Bakst R; Posner M
Anticancer Drugs; 2014 May; 25(5):561-70. PubMed ID: 24534821
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel, cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck.
Hussain M; Gadgeel S; Kucuk O; Du W; Salwen W; Ensley J
Cancer; 1999 Dec; 86(11):2364-9. PubMed ID: 10590379
[TBL] [Abstract][Full Text] [Related]
17. Taxanes in the treatment of head and neck cancer.
Schrijvers D; Vermorken JB
Curr Opin Oncol; 2005 May; 17(3):218-24. PubMed ID: 15818164
[TBL] [Abstract][Full Text] [Related]
18. Feasibility and efficacy of induction docetaxel, cisplatin, and 5-fluorouracil chemotherapy combined with cisplatin concurrent chemoradiotherapy for nonmetastatic Stage IV head-and-neck squamous cell carcinomas.
Prestwich RJ; Öksüz DÇ; Dyker K; Coyle C; Şen M
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e237-43. PubMed ID: 21620580
[TBL] [Abstract][Full Text] [Related]
19. Expanding role of the medical oncologist in the management of head and neck cancer.
Choong N; Vokes E
CA Cancer J Clin; 2008; 58(1):32-53. PubMed ID: 18096865
[TBL] [Abstract][Full Text] [Related]
20. Induction chemotherapy for head and neck cancer: recent data.
Vokes EE
Oncologist; 2010; 15 Suppl 3():3-7. PubMed ID: 21036882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
